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Abstract
Hypodiploid ALL is a rare subtype of ALL that is classified as having chromosomal
abnormalities in leukemic cells, resulting in cells that have less than forty-six
chromosomes. Poor clinical outcomes have been identified in patients with hypodiploid
ALL; however, the influence of harboring a TP53 germline mutation in this rare subtype
has not been previously studied. This study aims to determine if patients with
hypodiploid ALL who harbor a TP53 germline mutation have a worse clinical outcome
compared to patients with hypodiploid ALL who do not harbor a TP53 germline
mutation. This analysis includes 42 hypodiploid ALL patients, 18-years-old or younger,
from St. Jude Children’s Research Hospital. Patients with hypodiploid ALL who harbor a
TP53 germline mutation have a decreased overall survival (p = 0.0018), have an
increased risk of experiencing a relapse occurrence (p = 0.0069), and developing a
secondary malignancy (p = 0.0442).
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Chapter 1
Introduction
Acute Lymphoblastic Leukemia (ALL) is a cancer of the bone marrow that affects
the precursors to lymphocytes, an important white blood cell that helps to fight infection
in the body.
ALL is the most common childhood cancer (Mehta et al., 2015). In 2013, the
prevalence of ALL in the United States was reported to be approximately 77,855 people
living with the diagnosis (National Institute of Health, 2016). Furthermore, according to
the NIH in 2016, there were approximately 6,590 people in the United States diagnosed
with ALL; of those, two thirds were children (National Institute of Health, 2016; Pui &
Evans, 1998). The prevalence of ALL is slightly higher in males than in females, and
higher in whites than African Americans; however, the reasons for these differences are
unclear (American Cancer Society, 2017). The risk of a person developing ALL in their
lifetime is less than 1 in 750; the risk being the lowest in people who are in their mid-20s
and the highest among children who are younger than 5 years old (American Cancer
Society, 2017).
Hypodiploid ALL is a rare subtype of ALL in which leukemia cells have less than
45 chromosomes (Nachman et al., 2007). Hypodiploid ALL is associated with a poor
clinical outcome and decreased survival rates (Holmfeldt et al., 2013; Zhang et al., 2015).
Hypodiploidy can be divided into three subgroups: high-hypodiploid (40-45
chromosomes), low-hypodiploid (32-39 chromosomes), and near-haploid (24-31
chromosomes). Patients with greater than 45 chromosomes have a significantly increased
survival outcome compared to patients who have less than 45 chromosomes (Nachman et

1

al., 2007). Hypodiploidy is rare, affecting only 3% to 9% of ALL patients (Muhlbacher et
al., 2014; Pui et al., 1987).
Previous studies have discovered that patients who have hypodiploid ALL, more
specifically low-hypodiploid ALL, have a 43% chance of harboring a germline mutation
in a critical tumor suppressor gene known as TP53 (Holmfeldt et al., 2013). Harboring a
germline mutation means an individual carries a gene change that is present in every cell
of their body. TP53 encodes the protein p53, which regulates the expression of numerous
target genes, resulting in functions that include: cell cycle arrest, apoptosis, and assisting
in DNA repair (Olivier, Hollstein, & Hainaut, 2010). Research studies have concluded
that mutational inactivation of TP53 interferes with these important cellular processes
and is associated with development of a variety of cancers, including hypodiploid ALL.
A germline mutation in TP53 is associated with a condition classified as Li-Fraumeni
Syndrome (LFS) (Olivier et al., 2010). LFS is a hereditary predisposition syndrome that
increases the chance of an individual developing a wide spectrum of tumors. Unlike other
cancer predisposition syndromes that are site-specific, patients with LFS are prone to
developing 6 different types of cancer at early ages.
Rationale of the Study
The exact influence of harboring a TP53 germline mutation in patients with
hypodiploid ALL is poorly understood. Most commonly used chemotherapy drugs today,
utilize the cellular function of p53 to help target and destroy cancer cells; however, in
patients who have a loss in cellular function of p53 (i.e., patients with TP53 germline
mutations) their bodies cannot carry out the function of destroying cancer cells and they
will develop chemotherapy resistance, which is often characterized by relapse
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(Blagosklonny, 2002). Therefore, it is important to study clinical outcomes in patients
with TP53 germline mutations to better understand the potential effects associated with
chemotherapy resistance these mutations cause. In doing so, researchers can begin to
discover new courses of treatment that will help improve outcomes in these patients (such
as allogeneic transplantation; avoidance of radiation therapy due to second cancer risks,
etc).
Study Objectives
The overall objective of this study is to analyze clinical outcomes in patients with
hypodiploid ALL and to determine the effects of harboring a TP53 germline mutation.
There are four specific objectives.
1. Estimate the overall survival of patients with hypodiploid ALL who do and do not
harbor a TP53 germline mutation
2. Estimate the risk of relapse in patients with hypodiploid ALL who do and do not
harbor a TP53 germline mutation
3. Estimate the risk of secondary malignances in patients with hypodiploid ALL
who do and do not harbor a TP53 germline mutation
4. Evaluate hazard ratios for overall survival, risk of relapse, and development of
secondary malignancies in patients with hypodiploid ALL who do and do not
harbor a TP53 germline mutation
Hypothesis 1: hypodiploid ALL patients who harbor a TP53 germline mutation will have
decreased overall survival
Hypothesis 2: hypodiploid ALL patients who have a TP53 germline mutation will have
an increased risk of relapse and development of secondary malignancies
3

Justification of Research
While the overall survival rate for patients with ALL continues to rise, the overall
survival rate for patients with hypodiploid ALL remains poor due to the higher risk of
relapse (Bhojwani, Howard, & Pui, 2009). With that being said, when patients with
hypodiploid ALL begin therapy they are classified as “high-risk” because they are less
likely to respond well to therapy. These findings in the context of overall survival, relapse
rates, and development of secondary malignancies would be informative in exploring
different treatment options for this rare subtype, in hopes of improving clinical outcome.
Tailoring a patient’s therapy to the risk of relapsing is an important component in the
steps toward improving “cure rates and [minimizing] toxicities in childhood ALL”
(Bhojwani et al., 2009). Steps toward improving outcomes in patients who harbor a TP53
germline mutation should be done by increasing the knowledge of genetic influences on a
patient’s response to therapy and increasing the use of sequencing analysis to improve the
understanding of the TP53. The reason being is there might be an underlying
predisposition factor that we are currently unaware of.
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Chapter 2
Literature Review
ALL
Acute Lymphoblastic Leukemia is a pediatric and adult cancer of the bone
marrow and blood that affects the white blood cells that aid in fighting off infection in the
body. In addition to affecting the white blood cells in the bone marrow, ALL could
potentially affect the person’s red blood cells and platelets as well. ALL is one of four
main types of leukemia and is characterized by the overproduction of immature
lymphocytes (a type of white blood cell) in a person’s bone marrow. As leukemia cells in
the blood and bone marrow continue to rise there becomes less room for the healthy
white blood cells, red blood cells, and platelets to flourish and function properly.
Leukemia’s are a type of cancer that invades the blood very quickly. In addition to its
quick invasion, leukemia can also spread to surrounding areas such as lymph nodes, liver,
spleen, central nervous system (brain and spinal cord), and testicles (in males) (American
Cancer Society, 2017). According to the American Cancer Society, the term “acute” can
be attributed to the fact that the cancer can progress quickly, and if left untreated, could
be terminal within months. ALL is categorized into two main subtypes: B-cell ALL and
T-cell ALL. A process called immunophenotyping determines these two main subtypes; a
process in which blood samples are analyzed to determine the specific types of cells that
are present. In children with ALL, it is more common to see a B-cell lineage (85% to
90%) than a T-cell lineage (10% to 15%) (Heerema et al., 1999; Nachman et al., 2007;
Stengel et al., 2014).
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Overall Survival
Thanks to advances in treatment, ALL is one of the most treatable cancers with an
impressive 90% cure rate (Mehta et al., 2015; Pui & Evans, 1998; Stengel et al., 2014);
however, ALL used to be a fatal cancer. When St. Jude opened its doors in 1962, the
overall survival for children with ALL was only 20% (Pui & Evans, 2013). To address
the challenge of increasing the overall survival rate, researchers at St. Jude initiated a
therapeutic protocol termed “total therapy” that would include “multiple components of
therapy” that would later “form the backbone of ALL treatment today” (Pui & Evans,
2013). In 1967-1968, Total Therapy Study V had an overall survival of 50% for the
patients enrolled on the study. This success stimulated other laboratories around the
world to begin improvement of ALL treatment and by the late 1970s to early 1980s the
overall survival increased to 70%. In the early 1990s, the overall cure rate increased to
80% when researchers discovered that central-nervous-system (CNS)-directed therapy
with dexamethasone was better “than prednisone in preventing CNS relapse” (Pui &
Evans, 2013). Finally, based on a randomized study in early 2000s, researchers
discovered what is called “personalized dosing”, which refers to the dosing of
chemotherapy drugs based on a patient’s ability to clear them. By better defining the
pharmacokinetics and clearance of drugs, St. Jude investigators were able to achieve a
cure rate of 90%. In years to come, with the advancements of “whole genome and
transcriptome sequencing”, patients diagnosed with ALL will be “classified according to
their specific genetic abnormalities”, which will pave the road for the discovery of new
drugs and new therapeutic regimens (Pui & Evans, 2013).
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Hypodiploid ALL
Hypodiploid ALL is a rare subtype of ALL that is classified as having
chromosomal abnormalities in leukemic cells, resulting in cells that have less than fortyfive chromosomes (Nachman et al., 2007). Despite the improvements in overall therapy
for ALL in children, hypodiploid ALL remains associated with a poor prognosis and
“insufficient response to therapy” (Holmfeldt et al., 2013; Mullighan et al., 2015; Pui et
al., 1990; Stengel et al., 2014; Zhang et al., 2015). The reason for insufficient response to
therapy is, patients with hypodiploid ALL suffer large chromosomal losses that can be
associated with the reason for having a poor response to therapy (Pui et al., 1987). When
a patient suffers large chromosomal losses they are more likely to “lose their suppressor
genes or to express recessive oncogenes”, which could potentially lead to a “more
aggressive disease” (Pui et al., 1987). According to a study conducted by the Children’s
Oncology Group (COG), data pooled from 130 patients with hypodiploid ALL only had
an 8-year event free survival (EFS) of 38%; therefore, “patients with hypodiploid ALL
are currently treated on higher-risk protocols” (Bhojwani et al., 2009).
Since patients with greater than 45 chromosomes have substantially better
outcomes compared to patients who have less than 45 chromosomes (Nachman et al.,
2007), ascertaining chromosome number (ploidy) is important when determining
prognosis information for patients with ALL (Nachman et al., 2007; Pui et al., 1990).
Hypodiploidy can be cytogenetically divided into three distinct karyotype subgroups:
high-hypodiploid, which consists of 40-45 chromosomes, low-hypodiploid, which
consists of 32-39 chromosomes, and near-haploid, which consists of 24-31 chromosomes.
These three distinct karyotypes are each associated with their own set of clinical and
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prognostic factors; for example, studies have shown that patients with low-hypodiploid
ALL are diagnosed at an older age (i.e., over the age of 10 years old) compared to
patients with high-hypodiploid ALL (Pui et al., 1987). Therefore, conducting a
cytogenetics analysis is an important diagnostic tool to assess the ALL risk.
Hypodiploidy only affects 3% to 9% of patients diagnosed with ALL (Muhlbacher et al.,
2014; Pui et al., 1990) and only ~0.5% of pediatric patients are diagnosed with the two
subtypes of near-haploid and low-hypodiploid ALL (Safavi & Paulsson, 2017). The
reason for such large chromosomal losses in these patients with hypodiploid ALL is not
understood. Hopefully with increased research, development of better intensified
therapies, development of new chemotherapy agents, and “safer and more available stem
cell transplantation” physicians will be more effective in treating this rare subgroup of
ALL (Bhojwani et al., 2009; Pui et al., 1990).
TP53 Germline Mutation
The influence of harboring a germline mutation in hypodiploid ALL patients and
its effects on clinical outcomes such as overall survival, relapse occurrences, clinical
remission status, secondary primary malignancies, and qualifications for a bone marrow
transplant has not been previously reported. While the therapy regiment for patients
diagnosed with ALL has improved, it still “remains the most common cause of cancerrelated death” in children; however, with the advancements of genetic testing/profiling
there might be ways to decrease this statistic (Holmfeldt et al., 2013).
Harboring a germline mutation means an individual inherited a gene change that
is present in every cell of their body. In hypodiploid ALL patients, we are interested in
looking at germline mutations in the gene TP53. TP53 “is the most extensively studied”
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tumor suppressor gene in cancer today; however, its role in patients with ALL, more
specifically, low-hypodiploid ALL is poorly understood (Stengel et al., 2014). The reason
being is, TP53 cancer-associated mutations have been “very diverse in their location”
along the TP53 gene and there has been a wide range of techniques used (i.e., some
groups only screen exons five to eight using single strand conformation polymorphism
(SSCP) and others carry out more detailed studies) to identify mutations in the germline;
therefore, this makes it difficult to draw conclusions about the specific type of mutations
seen in the germline (Stengel et al., 2014; Varley, 2003). TP53 is a tumor suppressor
gene that regulates the expression of target genes, by inducing cell cycle arrest, apoptosis,
genomic stability, and assisting in DNA repair (Olivier et al., 2010; Stengel et al., 2014).
When TP53 suffers genetic alterations, it could potentially lead to the inactivation of its
functions listed above; therefore, leading to an uncontrollable growth of cells that, in turn,
can lead to the development of tumors. Studies have shown that when an individual is a
gene mutation carrier, their “lifetime cancer risk was estimated to be 73% in males and
nearly 100% in females who are prone to breast cancer” (Malkin, 2011). Other studies
have shown, chromosomal alterations in TP53 to include “missense, nonsense, and
insertion-deletion mutations”, which are notable as loss-of-function mutations; however,
the occurrence of a TP53 germline mutation is rare with a rate of about 1 in 5,000
individuals (Holmfeldt et al., 2013; Malkin, 2011). Interestingly, a loss-of-function in
TP53 occurs in 91% of tumor (somatic) cells and in 43% of nontumor (germline) cells in
patients with low-hypodiploid ALL; therefore, this suggests that the mutation is inherited
and is a hallmark for this particular subtype of ALL (Holmfeldt et al., 2013; Safavi &
Paulsson, 2017). This dominantly inheritance pattern in TP53 in patients with low-
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hypodiploid ALL can be attributed to a condition classified as Li-Fraumeni Syndrome in
children (LFS) (Holmfeldt et al., 2013; Olivier et al., 2010).
Li-Fraumeni Syndrome
LFS is a rare hereditary predisposition syndrome that increases the chance of an
individual developing a wide spectrum of tumors and it associated with the germline
mutation TP53 (Malkin, 2011; Nichols et al., 2001). At early ages, patients with LFS,
unlike other cancer predisposition syndromes that are site-specific, are prone to
developing six different types of cancer such as soft tissue sarcomas, osteosarcoma,
breast cancer, brain tumors, adrenocortical carcinoma, and leukemia (Nichols et al., 2001;
Valdez, Nichols, & Kesserwan, 2016; Varley, 2003). The onset of cancer at early ages
has been described as a “characteristic of virtually all hereditary cancers” (Nichols et al.,
2001). In addition, patients that have been termed carriers of p53 mutations could be
susceptible to developing other types of cancers, not listed above (Nichols et al., 2001).
When analyzing a family for the possibility of LFS, the proband is diagnosed with a
sarcoma under the age of 45 years, “who has a first-degree relative with any cancer under
45 years, plus another first-or second-degree relative with either any cancer under 45
years or a sarcoma at any age” (Malkin, 2011). An example of a family’s pedigree with
LFS is shown in Figure 1. Individuals with LFS, especially children, are also at an
increased risk for developing secondary primary malignances, in addition to the six
common types of cancer present in LFS patients (Malkin, 2011; Valdez et al., 2016).
When an individual has LFS and develops ALL, it presents in the ‘low’ hypodiploid
phenotype; therefore, genomic sequencing has shown TP53 alterations to be present in
most patients with low hypodiploid ALL (Holmfeldt et al., 2013; Valdez et al., 2016). As
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stated previously, TP53 has become a significant hallmark when analyzing pediatric, but
not adult patients with low-hypodiploid ALL (Holmfeldt et al., 2013; Mehta et al., 2015;
Valdez et al., 2016).
Risk Stratification
The treatment of ALL is based on a process of risk stratification, where the
intensity of chemotherapy administered differs depending on specific characteristics of
the patient and his or her leukemia. Risk stratification for ALL has evolved from defining
three risk groups: low-risk, standard-risk, and high-risk. Proposed risk classification
system for ALL is based on immunophenotype (i.e., B-cell ALL or T-cell ALL),
karyotype (i.e., high-hypodiploid, low-hypodiploid, and near-haploid), age at diagnosis
(i.e., <10 years old or >10 years old), white blood cell (WBC) count (i.e., >50,000/µL or
<50,000/µL), early response to therapy, and the presence of translocations that could
affect prognosis (Pui & Evans, 1998). Patients classified as low-risk have B-cell ALL, a
normal (i.e., 46 chromosomes) or hyperdiploidy (i.e., >50 chromosomes) karyotype,
diagnosed under the age of 10 years old, a WBC count <10,000/µL, have a good early
response to induction chemotherapy, and do not have the presence of any translocations.
Patients classified as high-risk have T-cell ALL, a low-hypodiploid karyotype (i.e., 32-39
chromosomes), diagnosed over the age of 10 years old, a WBC count that is >50,000/µL,
have a poor early response or failure of induction chemotherapy, and have the presence
of translocations. There is a certain subset of patients who have always been considered
high-risk such as patients who are positive for ALL type BCR/ABL, which is commonly
known as Philadelphia chromosome positive (Ph+) and is associated with poor prognosis
(Bhojwani et al., 2009). The Philadelphia chromosome is a translocation that occurs
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between chromosomes 9 and 22 and is designated as t(9;22)(q34;q11). The discovery of
Philadelphia chromosome is an example of the importance of analyzing the molecular
make up of a patient’s leukemia to determine whether there are features that could affect
his/her prognosis. There are many translocations that can be detected; however, the
translocations that are most commonly analyzed in the patient’s charts at SJCRH include:
BCR/ABL, E2A/PBX, MLL/AF-4, and TEL/AML-1 fusion transcripts. ALL is
categorized into two main subtypes: B-cell ALL and T-cell ALL. Using
immunophenotyping is important to assess whether a patient has B-Cell ALL or T-Cell
ALL because patients with pre-T-Cell ALL have a higher risk of treatment failure
(Bhojwani et al., 2009; Carroll et al., 2003). Age of diagnosis is another risk stratification
variable and an important prognostic factor for both incidence and survival of patients
with ALL (Jobayer Hossain, Xie, & McCahan, 2014). The lowest survival rate is
observed among patients who are diagnosed during infancy and children older than 10
years old (Jobayer Hossain et al., 2014; Pui & Evans, 1998). According to a study
conducted by children’s oncology group (COG), patients with hypodiploid ALL were
more likely to be older than 10 years older compared to patients with non-hypodiploid
ALL (Heerema et al., 1999). Patients’ WBC count at initial diagnosis is also predictive of
outcome (Carroll et al., 2003). WBC count can be stratified into low-risk classified as
WBC count<10,000/µL, standard-risk classified as 10,000/µL to 49,999/µL, and highrisk classified as WBC count ≥50,000/µL. Patients with central nervous system (CNS)
involvement at initial diagnosis falls will fall into the category of high-risk compared to
patients without CNS involvement who will be classified as standard-risk.
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Assessing Response via MRD
Predictions of long-term survival in patients with ALL are based on the “initial
response to the first few weeks of remission induction chemotherapy” (Bhojwani et al.,
2009). The assessment of a patient’s bone marrow status at the end of induction
chemotherapy is used to quantify response. A good response to therapy is defined having
less than <5% leukemic blasts in the bone marrow and having a minimal residual disease
(MRD) value of <0.01%, while showing full recovery of the normal hematopoietic
elements. Patients who have a positive MRD (>0.01%) at the end of induction are
classified as having a poor response to therapy and often require intensification of
treatment (Bhojwani et al., 2009; Paietta, 2002).
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Chapter 3
Materials and Methods
Recruitment of Participants
For this analysis, 42 patients, 18-years-old or younger, were recruited from St.
Jude Children’s Research Hospital (SJCRH). Based on karyotype analysis, patients who
had less than forty-five chromosomes and were enrolled on therapeutic protocols Total
XIII, Total XIV, Total XV, or Total XVI from January 1, 1991 to April 6, 2014 (end of
IRB approval) were eligible to be included in our study.
Of these forty-two patients, forty-one were SJCRH patients and one patient was
transferred to SJCRH to undergo a bone marrow transplant, after a hematological
hypodiploid ALL relapse and was seen in the Cancer Predisposition Clinic.
Data Collection
This study is a retrospective cohort, and data collection for this analysis consisted
of chart reviews and automated extraction from the electronic medical record (EMR) at
SJCRH.
Variables
Outcome Variables. The primary outcome of interest is overall survival.
Survival is defined as date of diagnosis to the end of our study period April 6, 2014 (end
of IRB approval), time to death, or lost to follow up. Secondary outcomes include the
development of a second primary malignancy and/or experiencing a relapse occurrence.
A second primary malignancy is defined as untreated cancers that arise independently
and not as the result of original tumor recurrence or metastasis (Feller & Lemmer, 2012).
Experiencing a relapse occurrence is defined as the morphologic recurrence of leukemia
14

(Mehta et al., 2015). These variables were also analyzed as time to event outcomes;
therefore, the time was calculated as date of diagnosis to the end of our study period, time
to occurrence of secondary malignancy and/or relapse, or lost to follow up, whichever
occurred first.
Exposure Variable. In our study, the exposure variable is whether or not patients
with hypodiploid ALL harbor a TP53 germline mutation. Next-generation sequencing
(NGS), including whole-exome and whole-genome sequencing was used on germline
(non-tumor) tissues obtained from all hypodiploid ALL patients to analyze the patients’
genomes to determine if a TP53 mutation was present.
Covariates. Additional demographic and clinical characteristics were assessed as
potential confounders. Demographic variables will include: gender, race, location of
residence, and family history of any cancer. Treatment related (i.e., treatment itself or
things that affect the course of treatment) variables included: therapeutic protocol the
patient was enrolled on (Total XIII, Total XIV, Total XV, or Total XVI) and if the
patients underwent any radiation therapy during their course of treatment, dichotomized
as yes or no. Variables associated with the risk of experiencing a relapse during the
course of therapy included: risk group recorded at initial diagnosis, either low-risk,
standard-risk, or high-risk, cell type defined as the lineage of ALL a patient was
diagnosed, B-Cell or T-Cell, and white blood cell count at diagnosis, dichotomized at
<50,000/µL vs. ≥ 50,000/ µL, and central nervous system (CNS) involvement at initial
diagnosis, dichotomized as yes or no. Karyotype subgroup will also be assessed is
defined as high-hypodiploid (40-45 chromosomes), low-hypodiploid (32-39
chromosomes), or near-haploid (24-31 chromosomes). In addition, we will analyze
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patients’ molecular pathology reports at initial diagnosis to assess whether they are
positive for BCR/ABL, E2A/PBX, MLL/AF-4, and TEL/AML-1 fusion transcripts at
initial diagnosis.
Statistical Methods
Demographic and clinical characteristic variables will be summarized for those
with, without, and those with unknown TP53 germline mutations. Since mutation status
is divided into three distinct categorical groups (positive TP53 mutation, negative TP53
mutation, and unknown TP53 mutation status) we will first create frequency tables for
each demographic and clinical characteristic variables stratified by mutation status. Next,
we will assess the differences between the three mutation status groups by implementing
Fisher’s exact tests.
Initially we will compare the crude survival time between patients with and
without TP53 germline mutations via Kaplan-Meier plots and Log-Rank test; for this
analysis, we will exclude those with unknown TP53 status. Next, the Cox proportional
hazard model will be implemented to estimate both the crude and adjusted hazard ratios
for patients with and without TP53 germline mutations; once again, excluding those with
unknown TP53 status. P-values less than 0.05 will be considered statistically significant
and no adjustments will be made for multiple comparisons (Rothman, 1990).
To determine the multivariable model, first, each of the covariates described
above will be evaluated as a potential confounder. First, we will assess each variable
based on the three criteria for confounding: (1) for a variable to be considered a
confounder it has to be associated with the exposure (causally or not) (2) the variable
must be associated with the outcome (i.e., overall survival), and, (3) it cannot be on the
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causal pathway between the exposure and outcome. Each variable meeting the three
criteria based on our assessment of the causal structure will then be evaluated statistically
using Cox regression. Potential confounders meeting the three criteria will be assessed
using the 10% rule. Each variable will be entered into the model one at a time and if the
hazard ratio for TP53 changes by more than 10% the variable will remain in the model.
The same procedures will be used to determine the crude and adjusted hazard
ratios for the secondary outcomes: relapse and the occurrence of secondary malignancy.
Bias Analysis
Missing data on the exposure variable (i.e., harboring a TP53 germline mutation)
is a potential source of selection bias in this study. After conducting our primary analysis,
we will conduct a bias analysis to quantify the potential impact of bias from missing
exposure data. The bias analysis will evaluate overall survival between patients with
TP53 germline mutations and those without TP53 germline mutations by randomly
assigning the patients with missing exposure data to the exposed group (the remained
being assigned to the unexposed group) in the following percentages: 0%, 20%, 40%,
60%, 80%, and 100%. This was done with a single random imputation for each scenario.
Adjusted estimates will then be presented for each scenario (Lash, Fox, & Fink, 2009).
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Chapter 4
Results
Of the 42 patients enrolled on our study, the overall survival of patients with
hypodiploid ALL who harbored a TP53 germline mutation was significantly different.
Table 1 displays the covariates gathered for the patients with hypodiploid ALL.
Of the 42 patients, more than half of the patients (N = 24) expressed a high-hypodiploid
karyotype (i.e., 40-45 chromosomes), a quarter of the patients (N = 11) expressed a lowhypodiploid karyotype (i.e., 32-39 chromosomes), and the remaining patients (N = 7)
expressed a near-haploid karyotype (i.e., 24-31 chromosomes). The majority of the
patients were either enrolled on Total XIII (N = 14) or Total XV (N = 15), followed by
the remaining being enrolled on either Total XIV (N = 7), Total XVI (N = 5); one patient
was not treated on any of the therapeutic protocols because the patient was not diagnosed
at SJCRH. Approximately, 31% of the patients received radiation therapy during their
course of treatment. Patients described as “high-risk” at initial diagnosis (N = 36) were
most common, followed by “standard-risk” and “low-risk” with the same number of
patients in each of the two risk classification groups (N = 3). Approximately, 93% of
patients were diagnosed with B-cell ALL, while the remaining 7% were diagnosed with
T-cell ALL. WBC count ≤ 50,000/µL at initial diagnosis was observed in 73% of patients
compared to 27% of patients who had a WBC count ≥50,000/µL. Translocation present,
such as Ph+ chromosome, was discovered in 16% patients, CNS involvement at initial
diagnosis was only recognized in 38% patients, and 88% patients had a positive family
history of cancer.
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Table 2 displays the characterization of patient demographics and clinical
characteristics stratified by TP53 positive, TP53 negative, and TP53 unknown mutation
status. Analysis of the TP53 mutation frequency in the total cohort revealed 5 of 42 to be
TP53 positive, 23 of 42 to be TP53 negative, and 14 of 42 to have an unknown TP53
mutation status. There was a slightly higher frequency of males (N = 22) than females (N
= 20), a greater frequency of whites (N = 31) than Asian (N = 1), African American (N =
7), Hispanic (N = 1), or other (N = 2), and a higher frequency of patients from
surrounding states (N = 29) than from Tennessee (N = 13). In addition, there was a higher
frequency of patient’s diagnosed ≤ 10 years old (N = 27) than patients diagnosed ≥10
years of age (N = 15). The mean age of diagnosis was 7.5 (standard deviation: 5.1).
Among the 13 demographic and clinical characteristic variables, there was only a
statistically significant (p <0.05) association found between the 3 groups (i.e., TP53
positive, TP53 negative, and TP53 unknown), and age of diagnosis ≥10 years old (p =
0.038), radiation (p = 0.0070), and karyotype (p = 0.001). The remaining variables were
not significantly associated with TP53 status.
Outcome Variables
Table 3 displays frequencies of the outcomes assessed in the total cohort. Relapse
occurred in 19% of the patients and 10% of patients developed a secondary malignancy.
All patients (N = 41) except one achieved clinical remission at the end of induction
chemotherapy treatment and 89% had a negative MRD status at the end of induction
chemotherapy treatment. A bone marrow transplant was received among 19% patients
and 74% of patients were still alive at the end of the study. Table 4 displays the
characterization of patient outcome variables stratified by TP53 positive, TP53 negative,
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and TP53 unknown mutation status. Among the six outcome variables, there was only a
statistically significant (p <0.05) association found between the three TP53 statuses and
survival status (p = 0.0003), having a bone marrow transplant (p = 0.006), and relapse
occurrence (p = 0.006). The remaining values were not significantly associated with
TP53 status.
Overall Survival
First, we wanted to assess overall survival among patients diagnosed with
hypodiploid ALL (Figure 2). Next, we wanted to assess if there was an association
between harboring a germline mutation and overall survival (Figure 3). Overall survival
was significantly different between hypodiploid ALL patients who harbored a TP53
germline mutation and hypodiploid ALL patients who did not harbor a TP53 germline
mutation (log rank, p <0.001).
Table 5 displays the 3, 5, and 10 year overall survival estimates for patients with
hypodiploid ALL who do and do not harbor a TP53 germline mutation. Patients with a
positive TP53 germline mutation have 3 year overall survival of 40% (95% CI: 30%,
50%) compared to patients with a negative TP53 germline mutation who have an overall
survival of 100% (95% CI: not measurable).
Using the Cox proportional hazard model, we found a statistically significant
association between harboring a TP53 germline mutation and overall survival (p < 0.05).
In patients with hypodiploid ALL, those harboring a TP53 mutation have 36.1 times the
hazard of death (95% CI: 3.81, 341.4) compared to those without the mutation. Table 6
displays the potential confounders assessed in our study. Based on the criteria for a
confounder by looking at the biological pathways, three of the variables, age of diagnosis,
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CNS involvement, and family history satisfied all three requirements to be a confounder.
However, after applying the 10% rule, we discovered that only age of diagnosis was a
confounder. Table 7 displays the adjusted model for overall survival in patients with
hypodiploid ALL who harbor a TP53 germline mutation, while adjusting for age of
diagnosis. Due to sparse data, we were unable to adjust for both CNS involvement and
age at diagnosis >10 years old; therefore, these analyses are adjusted for age at diagnosis
only. Adjusted for age at diagnosis >10 years old, those with TP53 mutation have 120.7
times (95% CI: 5.0, 2919.4) the hazard of death compared to those without the mutation.
Relapse Occurrence
Additionally we wanted to assess the probability of experiencing a relapse
occurrence among patients diagnosed with hypodiploid ALL (Figure 4) and to assess if
there was an association between harboring a germline mutation and experiencing a
relapse occurrence (Figure 5). Experiencing a relapse occurrence was significantly
different between hypodiploid ALL patients who harbored a TP53 germline mutation and
hypodiploid ALL patients who did not harbor a TP53 germline mutation (log rank, p
<0.0001).
Using the Cox proportional hazard model, we found the crude association
between harboring a germline mutation and experiencing a relapse occurrence to be
statistically significant (p <0.05). Those having a TP53 germline mutation have 25.9
times (95% CI: 2.4, 274.9) the hazard of experiencing a relapse occurrence than those
who do not harbor a TP53 germline mutation. Table 8 displays the adjusted model for
experiencing a relapse occurrence in patients with hypodiploid ALL who harbor a TP53
germline mutation, while adjusting for age of diagnosis. Due to sparse data, we were
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unable to adjust for both CNS involvement and age at diagnosis >10 years old; therefore,
these analyses are adjusted for age at diagnosis only. Adjusted for age at diagnosis >10
years old, those with TP53 mutation have 85.5 times the hazard of experiencing a relapse
occurrence (95% CI: 3.5, 2092.9) compared to those without the mutation.
Secondary Malignancies
We originally wanted to assess the probability of developing a secondary
malignancy among patients diagnosed with hypodiploid ALL (Figure 6). When we
assessed if there was an association between harboring a TP53 germline mutation and
developing a secondary malignancy (Figure 7), we discovered the rate of developing a
secondary malignancy was significantly different between hypodiploid ALL patients who
harbored a TP53 germline mutation and hypodiploid ALL patients who did not harbor a
TP53 germline mutation (log rank, p <0.0114). However, due to a small sample size and
only 4 of 42 patients developing a secondary malignancy, we were able to only
implement a crude Cox proportional hazard model. We found the crude association
between harboring a germline mutation and developing a secondary malignancy to be
statistically significant (p <0.05). Those having a TP53 germline mutation have 12.4
times (95% CI: 1.1, 144.6) the hazard of developing a secondary malignancy than those
who do not harbor a TP53 germline mutation. When adjusting for age of diagnosis in the
Cox proportional hazard model, the measures of association were inestimable.
Bias Analysis
To quantify the impact of missing data on the exposure variable (i.e., harboring a
TP53 germline mutation), we conducted a bias analysis. The bias analysis evaluated
overall survival between patients with TP53 germline mutations and those without TP53
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germline mutations by randomly assigning the patients with missing exposure data to the
exposed group (the remained being assigned to the unexposed group) in the following
percentages: 0%, 20%, 40%, 60%, 80%, and 100%. Table 9 reports the adjusted hazard
ratios, 95% confidence intervals, and 5 year overall survival for patients with and without
TP53 germline mutations for missing exposure data. The bias corrected hazard ratios
vary between 5.3 and 18.3, indicating that selection bias may cause an overestimation of
the hazard ratio. However, under every scenario, the hazard ratio was > 1; therefore, this
validates the association between overall survival and the exposure (i.e., harboring a
TP53 germline mutation), but we may not be able to accurately estimate magnitude of
this affect.
We also evaluated the impact of missing exposure data on the 5 year overall
survival for the unknown mutation status group by using the % missing exposed (i.e., 0%,
20%, 40%, 60%, 80%, and 100%) and having them be classified as either TP53 positive
or TP53 negative. These results (Table 9) support the findings above, that bias away from
the null hypothesis is a possibility.
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Chapter 5
Discussion
Hypodiploid ALL is characterized as a rare subtype of ALL. In previous studies,
poor clinical outcomes have been identified in patients with hypodiploid ALL (Mullighan
et al., 2015; Pui et al., 1990; Stengel et al., 2014); however, the influence of harboring a
TP53 germline mutation in this rare subtype has not been previously studied. To our
knowledge, this study comprises the first analysis of clinical outcomes in patients with
hypodiploid ALL who harbor a TP53 germline mutation.
As speculated, we confirmed both of our hypotheses that (1) patients with
hypodiploid ALL who harbor a TP53 germline mutation have a decreased overall
survival compared to patients with hypodiploid ALL who do not harbor a TP53 germline
mutation and (2) patients with hypodiploid ALL who harbor a TP53 germline mutation
are at an increased risk for experiencing a relapse occurrence compared to patients with
hypodiploid ALL who do not harbor a TP53 germline mutation. As previous studies have
concluded, our data also clearly shows that there is a higher frequency of males (52%)
diagnosed with hypodiploid ALL than females (48%), a higher frequency of whites
(74%) diagnosed than any other race, and a higher frequency of patients diagnosed ≤10
years old (64%). In addition, our results found that, patients with ALL are more likely to
be diagnosed with B-cell ALL (93%) than T-cell ALL (7%). The data also clearly shows
that the frequency of TP53 germline mutations (4 of 5 patients with TP53 germline
mutations) increase with the age of diagnosis (i.e., ≥10 years old). When analyzing the 5year overall survival in patients with and without TP53 germline mutations there is a
distinct comparison between these two groups. Patients without a TP53 germline
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mutation have an estimated 100% (CI: not measurable) survival at 5 years; however,
patient with a TP53 germline mutation, have only an estimated 20% (CI: 10%, 30%)
survival at 5 years. Despite our small sample size, we found a statistically significant
difference between harboring a TP53 germline mutation and overall survival.
Unfortunately, 14 of our patients did not have available sequencing data on the exposure
(i.e., harboring a TP53 germline mutation); therefore, a bias analysis was conducted to
evaluate the impact of missing data. The bias analysis found that it is possible that the
missing data has created an artifically inflated hazard ratio (bias away from the null
hypothesis); however, even the most extreme scenerios of bias towards the null
hypothesis showed a marked survival advantage in patients who where TP53 negative. It
is also possible that the pattern of exposure status in the missing data was more complex
than those evaluated in this bias analysis, which, in some circumstances, could have
created bias away from the null hypothesis (underestimating the true hazard ratio).
Holmfeldt et al., 2013, concluded that 43% of patients who harbored a TP53
germline mutation presented in the low-hypodiploid karyotype. Interestingly, 100% of
our patients with TP53 germline mutations presented in the low-hypodiploid karyotype;
therefore, representing that harboring a TP53 germline mutation is a significant hallmark
for patients with low-hypodiploid (i.e., 32-39 chromosomes) ALL. With the high
frequency of TP53 germline mutations in childhood patients with low-hypodiploid ALL,
we can conclude that this is a very distinct subtype and is a manifestation of LFS;
therefore, increasing genetic testing/counseling in families is important. In addition, these
patients with low-hypodiploid ALL who harbor a TP53 germline mutation and survive
are at an increased risk for developing secondary malignancies. However, we were
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unable to account for the association between harboring a TP53 germline mutation and
developing a secondary malignancy due to competing risks. Patients with hypodiploid
ALL who harbor a TP53 germline mutation have a decreased overall survival; therefore,
it is hard to analyze the development of secondary malignancies because they do not live
long enough to have the chance of developing a secondary malignancy (i.e., competing
risk).
It is proposed that all patients with hypodiploid ALL, more specifically lowhypodiploid ALL, receive genomic analysis before beginning therapy. This is because,
despite therapeutic protocol stratification of high-risk patients, this population continues
to do poorly on current therapies implemented and the need for developing more
effective targeted therapy for this subgroup is important. Current therapy regimens utilize
the cellular function of p53 (i.e., the protein encoded by the gene TP53), to induce
apoptosis (i.e., cell death), to destroy cancer cells in the body; however, patients with
TP53 germline mutations cannot utilize this cellular function. Therefore, if their bodies
are unable to utilize this cellular function then the current chemotherapy regimens are
unable to destroy the cancer cells growing in the body. In addition, patients with TP53
germline mutations will often develop chemotherapy resistance, which is usually
characterized by a relapse; however, what is interesting is that all patients 97.6%
achieved clinical remission at the end of induction chemotherapy except for one patient.
Additionally, the one patient that didn’t achieve clinical remission at the end of induction
chemotherapy did not harbor a TP53 germline mutation. Furthermore, none (0 of 5) of
the patients with TP53 germline mutations had a positive MRD status at the end of
induction chemotherapy. This is interesting because, Mullighan et al., 2015, recently
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published that assessing MRD values is helpful in determining event-free survival of
patients undergoing therapy; however, 0% of patients with a TP53 germline mutation had
a positive MRD at the end of induction chemotherapy suggesting that they should have
continued to remain event-free. Additionally, Safavi and Paulsson, concluded that
patients with negative MRD values were suggested as patients who “may be curable with
intensive chemotherapy”; however, this was not the case for the five TP53 positive
patients on our study. Therefore, future research needs to be conducted to understand
why these patients with TP53 germline mutations respond very well through the
induction phase of chemotherapy, but at some point stop responding and potentially
experience a relapse and develop secondary malignancies. Thus, further analyses of the
therapy regimens for patients with low-hypodiploid ALL needs to be conducted.
Strengths
The study conducted here had many strengths. First, this retrospective cohort
study is linked to the St. Jude Children’s Research Hospital-Washington University
Pediatric Cancer Genome Project (PCGP); described as a collaborative effort to assess
more than 800 St. Jude patient’s genomes to discover the underlying genetic causes of
some of the rarest forms of pediatric cancer (St. Jude Children’s Research Hospital,
2015). By this study being linked to the St. Jude PCGP, we were able to produce high
quality data and genomic sequencing; additionally, this study was the largest genomic
sequencing study to date. Even though our sample size was small, 28 of our 42 patients
had genomic sequencing available for us to analyze. To date, this is the largest sample
size of sequencing data on this specific rare type of cancer.
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Limitations
When assessing the results of this study, as in other epidemiological studies,
remember that it is not without limitations. First, not all genomic sequencing data was
available on all 43 patients, which lead us to have missing exposure data (i.e., whether or
not the patient harbored a TP53 germline mutation) on 14 patients. By having missing
data on 14 patients this could potentially cause bias away from the null hypothesis, which
means that our observed values could be overinflated compared to the true values.
However, five of these 14 patients expressed a low-hypodiploid ALL karyotype. The
mutation status of those five patients would have been especially important because they
had a 43% chance of harboring a TP53 germline mutation, which could have potentially
increased our number of patients with this mutation. This was a retrospective cohort
study conducted on patients undergoing treatment at SJCRH; therefore, it has potential
for selection bias. Selection bias could potentially arise in this study because analyzing
patients from a single hospital has the ability to produce results that are not a true
representation of the target population (i.e., all patients with hypodiploid ALL).
Additionally, our study includes a very rare subtype of ALL patients; therefore, this
results in having a small sample size, leading to a decreased statistical power. In addition
to having a small sample size, when conducting our Cox proportional adjusted model, we
relaxed the 7 to 10 covariate rule to conduct our analysis. Another limitation is that the
treatment the patients undergo at SJCRH is not a true representation of the treatment
patients will undergo at other facilities. St. Jude is the only hospital that treats their ALL
and hypodiploid ALL patients according to personalized dosing, which includes specific
pharmacokinetics and the patient’s ability to clear drugs from their body. In addition,
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SJCRH does not charge their patients and families for treatment, food, or living;
therefore, the patients are able to receive the optimal course of treatment, regardless of
insurance coverage. Unfortunately, at other facilities this is not necessarily the case for a
magnitude of reasons such as patients not having insurance, patients not being able to
afford the best course of treatment, and patients not being able to attend regular hospital
visits.
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Chapter 6
Conclusion
There are still many questions concerning this rare subtype and the exact
influence of harboring a TP53 germline mutation. The effects of harboring a TP53
germline mutation are detrimental and often associated with decreased overall survival;
however, patient’s response to therapy and how to effectively treat these patients remain
unclear. Since TP53 encodes the protein p53, which carries out all the cells important
functions, it is first important to understand the bodies’ cellular function when p53 is
absent. In addition to understanding the cellular function absent p53, it is important to
understand how these mutations have an effect on clinical outcome; therefore, it is
important to start incorporating genomic analysis to understand the exact influence of
these mutations. In addition, genomic analysis is relatively new to the world of cancer
research; therefore, the more researchers start utilizing it, the more we can begin to
discover about these mutations and their effect.
Future Directions/Recommendations
Tumor and germline genomic analyses/sequencing should be conducted on all
patients with hypodiploid ALL. Novel therapies for patients who harbor a TP53 germline
mutation need to begin with an understanding of the pharmacokinetics and drug clearance
of this rare subgroup; therefore, we can minimize chemotherapy resistance that will, in
turn, decrease the risk of relapse occurrences.
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Tables
Table 1 Covariates
Variable

Frequency
(N=42)

Percent (%)

24
11
7

57%
26%
17%

14
7
15
5
1

33%
17%
36%
12%
2%

36
3
3

86%
7%
7%

39
3

93%
7%

11
30
1

27%
73%
0

16
26

38%
62%

5
26
11

16%
84%
0

13
29

31%
69%

36
5
1

88%
12%
0

Karyotype
High (40-45 chromosomes)
Low (32-39 chromosomes)
Near (24-31 chromosomes)
Therapeutic Protocol
13
14
15
16
Other
Risk Group
High Risk
Low Risk
Standard Risk
Cell Subtype
B-Cell
T-Cell
WBC Count >50,000
Yes
No
Missing
CNS Involvement
Yes
No
Translocation Present
Yes
No
Missing
Radiation
Yes
No
Family History of Cancer
Yes
No
Missing
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Table 2 Baseline demographics and clinical characteristics of patients included on our
study (N = 42), stratified by mutation status
TP53 Status

N (%)

TP53
unknown
N (%)

Total
(%)

3 (7)
2 (5)

12 (29)
11(26)

5 (12)
9 (21)

20 (48)
22 (52)

0.6083

0 (0)
1 (2)
0 (0)
3 (7)
1 (2)

1 (2)
3 (7)
0 (0)
18 (43)
1 (2)

0 (0)
3 (7)
1 (2)
10 (24)
0 (0)

1 (2)
7 (17)
1 (28)
31 (74)
2 (5)

0.5064

0 (0)
5 (12)

6 (14)
17 (41)

7 (17)
7 (17)

13 (31)
29 (69)

0.0988

4 (10)
1 (2)

5 (12)
18 (43)

6 (14)
8 (19)

15 (36)
27 (64)

0.0376

5 (12)
0 (0)

21 (50)
2 (4.76)

13 (31)
1 (2)

39 (93)
3 (7)

1

2 (5)
3 (7)

9 (21)
14 (33)

5 (12)
9 (21)

16 (38)
26 (62)

1

1 (2)
3 (7)
1 (0)

7 (17)
16 (39)
0 (0)

3 (7)
11 (27)
0 (0)

11 (27)
30 (73)
1 (0)

0.8721

TP53 +

TP53 –

N (%)

P-Values

Gender
Female
Male
Race
Asian
Black
Hispanic
White
Other
State of Residence
Tennessee
Other
Age
≥10 years old
≤10 years old
Cell Subtype
B-Cell
T-Cell
CNS Involvement
Yes
No
WBC Count
>50,000
<50,000
Missing
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Table 2 Continued baseline demographics and clinical characteristics of patients included
on our study (N = 42), stratified by mutation status
TP53 Status

N (%)

TP53
unknown
N (%)

Total
(%)

PValues

0 (0)
5 (12)
0 (0)

15 (36)
2 (5)
6 (14)

9 (21)
4 (10)
1 (2)

24 (57)
11 (26)
7 (17)

0.0012

0 (0)
3 (10)
2 (0)

4 (13)
13 (42)
6 (0)

1 (3)
10 (32)
3 (0)

5 (16)
26 (83)
11 (0)

0.7799

4 (10)
1 (2)
0 (0)

19 (46)
3 (7)
1 (0)

13 (32)
1 (2)
0 (0)

36 (88)
5 (12)
1 (0)

0.813

5 (12)
0 (0)
0 (0)

18 (43)
3 (7)
2 (5)

13 (31)
0 (0)
1 (2)

36 (86)
3 (7)
3 (7)

0.7051

2 (5)
0 (0)
2 (5)
0 (0)
1 (0)

8 (19)
3 (7)
9 (21)
3 (7)
0 (0)

4 (10)
4 (10)
4 (10)
2 (5)
0 (0)

14 (33)
7 (17)
15 (36)
5 (12)
1 (0)

0.5573

4 (10)
1 (2)

3 (7)
20 (48)

6 (14)
8 (19)

13 (31)
29 (69)

0.007

7.5
5.6

STD
Range

5.1
1.2-17.5

TP53 +

TP53 –

N (%)
Karyotype
High
Low
Near
Translocation Present
Yes
No
Missing
Family Cancer History
Yes
No
Missing
Risk Group
High
Standard
Low
Therapeutic Protocol
13
14
15
16
Other
Radiation Therapy
Yes
No
Age
Mean
Median
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Table 3 Table for Outcome Variables
Frequency
(N=42)

Percent
(%)

Yes

8

19

No

34

81

41

98

No
MRD Status
(End of Induction Chemotherapy)
Positive

1

2

4

11

Negative

31

89

Missing Data

7

0

Yes

8

19

No

34

81

Yes

4

10

No

38

90

Alive

31

74

Expired

11

26

Time to Event Variables
Relapse

Achieved Clinical Remission
(End of Induction Chemotherapy)
Yes

Bone Marrow Transplant

Development of 2nd Cancer

Survival Status
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Table 4 Outcome Variables Stratified by Mutation Status

Relapse
Yes
No
Achieved
Remission (At the
End of Induction)
Yes
No
MRD Status (End
of Induction)
Positive
Negative
Missing
Data
Bone Marrow
Transplant
Yes
No
Development of 2nd
Cancer
Yes
No
Survival Status
Alive
Expired

TP53 +
Frequencies (%)

TP53 Status
TP53 –
Frequencies (%)

TP53 unknown
Frequencies (%)

Total (%)

3 (7)
2 (5)

1 (2)
22 (52)

4 (10)
10 (24)

8 (19)
34 (81)

5 (12)
0 (0)

22 (52)
1 (2)

14 (33)
0 (0)

41 (98)
1 (2)

0 (0)
4 (11)

3 (9)
15 (43)

1 (3)
12 (34)

4 (11)
31 (89)

1 (0)

5 (0)

1 (0)

7 (0)

3 (7)
2 (5)

1 (2)
22 (52)

4 (10)
10 (24)

8 (19)
34 (81)

2 (5)
3 (7)

1 (2)
22 (52)

1 (2)
13 (31)

4 (10)
38 (91)

1 (2)
4 (10)

22 (52)
1 (2)

8 (19)
6 (14)

31 (74)
11 (26)
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Table 5 3, 5, 10 Year Overall Survival for Patients With and Without Germline Mutations
3, 5, 10 Year Overall Survival
TP53 + Mutation
Time
(Years)

Overall
Survival

3
5
10
TP53 – Mutation
3

0.4000
0.2000
0.2000
1.000

5

1.000

10

0.9500

Lower 95%
Confidence
Interval
0.254
0.096
0.096

Lower 95%
Confidence
Interval
0.542
0.33077
0.33077

Not
measureable
Not
measureable
Not
measureable

Not
measureable
Not
measureable
Not
measureable
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# at risk

# of failed

3
2
2

3
4
4

23

0

23

0

15

1

Table 6 Table of Potential Confounders for Overall Survival

Gender
Race
Location of residence
Age of Diagnosis
Cell Type
CNS Involvement
Radiation
WBC
Karyotype
Translocation
Family History
Risk Category
Protocol

Criteria for a Confounder
Causally
Associated Associated
Not on
with
with
Causal
Exposure
Outcome
Pathway
No
Yes
Yes
No
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
No
Yes
Yes
Yes
Yes
No
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
No
Yes
Yes
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Potential
Confounder

Impact
HR by
10%

No
No
No
Yes
No
Yes
No
No
No
No
Yes
No
No

N/A
N/A
N/A
25.20%
N/A
83.41%
N/A
N/A
N/A
N/A
-1.12%
N/A
N/A

Table 7 Adjusted Model for Overall Survival

Final Model

TP53 Status

Adjusted
HR

95%
Confidence
Interval

P-value

120.7

5.0, 2919.4

0.0032

4.7

0.3-67.1

0.2576

Age> 10 years

Table 8 Adjusted Model for Experiencing a Relapse Occurrence
Final
Model

Adjusted
HR

95% Confidence
Interval

P-value

TP53
Status

85.5

3.5-2092.9

0.0064

Age>10
years

5.067

0.3-75.3

0.2386
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Table 9 Bias Analysis of Mutation Status
Unadjusted (Crude)
Variable

Crude HR

Mutation Status

36.1

95% Confidence
Interval
3.8-341.4

Adjusted HR
% Missing Exposed

Adjusted HR

95% Confidence
Interval

5 Year Survival
TP53 +

TP53 -

0

6.8

1.9-23.9

0.2

0.9

20

10.2

3.0-34.6

0.3

0.9

40

8.1

2.3-28.1

0.4

0.9

60

5.3

1.5-18.2

0.5

0.9

80

5.5

1.4-20.7

0.6

0.9

100

18.3

2.3-143.6

0.5

1
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Figures

Figure 1 An example of a family’s pedigree with LFS. “Filled circles/square represent
affected member; slashes represent deceased family members. Numbers represent age at
diagnosis. BB=bilateral breast cancer; CNS=brain tumor; BR=unilateral breast cancer;
LK=leukemia; CPC=choroid plexus carcinoma; RMS=Rhabdomyosarcoma;
OS=osteosarcoma” (from Malkin, 2011)
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Figure 2 Kaplan-Meier Analysis of Overall Survival Among Cases of Childhood
Hypodiploid ALL
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Figure 3 Kaplan-Meier Analysis of Overall Survival Among Cases of Childhood
Hypodiploid ALL Stratified by Mutation Status
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Figure 4 Kaplan-Meier Analysis of Relapse Occurrence Among Cases of Childhood
Hypodiploid ALL
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Figure 5 Kaplan-Meier Analysis of Experiencing a Relapse Occurrence Among Cases of
Childhood Hypodiploid ALL Stratified by Mutation Status
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Figure 6 Kaplan-Meier Analysis of Developing a Secondary Malignancy Among Cases
of Childhood Hypodiploid ALL
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Figure 7 Kaplan-Meier Analysis of Developing a Secondary Malignancy Among Cases
of Childhood Hypodiploid ALL Stratified by Mutation Status
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Appendix
Appendix A: Supplemental Table 1 (No’s from Table X included)
TP53 Unadjusted Model

Crude
HR
36.1

Adjusted For
Cell Type
CNS Involvement
Radiation
WBC
Karyotype
Translocation
Family History
Risk Category
Protocol

Adjusted
HR
32.7
2.43E+09
32.2
1.83E+09
8.82E+08
6.39E+10
34.7
27.7
1.70E+09
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95%
Confidence
Interval
3.8-341.4
95%
Confidence
Interval
3.5-309.3
Not measurable
0.7-1488.9
Not measurable
Not measurable
Not measurable
3.6-331.0
2.9-260.9
Not measurable

%Change
-2.81%
83.41%
-3.30%
83.19%
82.59%
85.59%
-1.12%
-8.03%
83.13%
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